Novo Nordisk CEO Criticises $49 Compounded Wegovy Pill as “Waste of Money”

The chief executive has criticized a $49 compounded version of its blockbuster weight-loss drug Wegovy, calling it a “waste of money,” according to a report.

The remarks were directed at a lower-cost compounded pill being promoted by a telehealth platform. Compounded medications are typically produced by specialized pharmacies and are not the same as brand-name drugs approved through full regulatory review.

Concerns Over Compounded Versions

Novo Nordisk has consistently cautioned against the use of compounded alternatives to its GLP-1 weight-loss medications, arguing that such products may not meet the same safety, efficacy, and quality standards as approved formulations.

Compounded drugs can be legally produced under certain conditions, particularly during shortages of brand-name medications. However, pharmaceutical manufacturers have raised concerns about potential variability in ingredients and dosing.

Growing Demand for Weight-Loss Treatments:

Wegovy has seen surging global demand amid increasing interest in GLP-1-based obesity treatments. High prices and supply constraints have led some patients to seek more affordable or accessible alternatives.

The debate highlights broader tensions between brand-name drugmakers and compounding pharmacies as demand for weight-loss therapies continues to rise.

Regulatory and Market Implications:

Regulators have emphasized that compounded medications are not evaluated in the same way as fully approved drugs. Industry analysts say the controversy underscores ongoing challenges related to affordability, supply, and patient access in the fast-growing obesity treatment market.

As competition intensifies and new formulations enter the market, scrutiny over pricing and safety standards is expected to remain high.